

**Figure S1** The expression patterns of representative differentially expressed AS (DEAS) events identified based on TCGA datasets. (A) Splicing pattern of SLK/STX2/CLSTN1/NFYA in breast cancer (BRCA) and their paired normal tissues (n=6) as detected by RT-PCR. Percent-Spliced-In (PSI) were presented under the gels. (B) Paired scatter plots depicted the RT-PCR results of SLK/STX2/CLSTN1/NFYA. Paired *t*-test was used.

Table S1 Sequences of RT-PCR primers

	1
Name	Sequences
SLK-F	GCCTGGAACAAGAGCACACA
SLK-R	TCCCAAATTGCAGCTTCTCG
STX2-F	CCACAGACTATGTAGAACACGCT
STX2-R	TCCAAGGATCACAAGCAAAACAA
CLSTN1-F	GAGGATTACCCGCTCCATCC
CLSTN1-R	CCTCTGCCACTGTCTTCGAG
NFYA-F	GAGCAGATTGTTGTCCAGGC
NFYA-R	GGGTTGGCCAGTTGATGTGA

Table S2 Clinical characteristics of TCGA BRCA cohort

Table S2 Clinical characteristics of TCGA BRCA cohort			
Characteristics	No. of patients (%), (n=930)		
Age			
Median	61(53-68)		
<60	509(54.7%)		
≥60	421(45.3%)		
Histology			
ILC	658(70.8%)		
IDC	188(20.2%)		
Others	84(9.0%)		
Т			
T1	245(26.3%)		
T2	540(58.1%)		
T3	123(13.2%)		
T4	22(2.4%)		
N			
N0	445(47.8%)		
N1	324(34.8%)		
N2	97(10.4%)		
N3	64(6.9%)		
Stage			
1	167(18.0%)		
II	541(58.2%)		
III	208(22.4%)		
IV	14(1.5%)		
ER			
Positive	718(77.2%)		
Negative	212(22.8%)		
PR			
Positive	631(67.8%)		
Negative	299(32.2%)		
Subtype_PAM50			
Normal	116(12.5%)		
LumA	448(48.2%)		
LumB	155(16.7%)		
Her2	61(6.6%)		
Basal	150(16.1%)		
Relapsed/Progressed			
No	834(89.7%)		
Yes	96(10.3%)		
Death			
No	811(87.2%)		
Yes	119(12.8%)		
	· · · · · · · · · · · · · · · · · · ·		